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Abstract
Introduction: Triple-negative breast cancer (TNBC) is defined as a group of breast carcinomas that are negative for
expression of hormone receptors (ER, PR) and Her2, we can distinguish between two groups: basal-like (ER-, PR-,
Her2-, cytokeratin (CK) 5/6+ and/or Her1+) and unclassified subtype (ER-, PR-, Her2-, Her1- and CK5/6-).
The aim of this study is to determine the clinicopathological, histological, therapeutic and prognostic features
associated with this type of breast cancer.
Methods: This is a retrospective study of 366 female breast cancer patients, diagnosed between January 2007 and
June 2010 at the Department of Pathology. Epidemiological, clinical, histological, therapeutic and evolutive data
were analyzed. OS and DFS rates were estimated by Kaplan-Meier analysis and a log-rank test to estimate outcome.
Results: A total of 64 women were identified as having TNBC (17.5% of all female breast cancer patients), 12.6%
were basal-like, 4.9% were unclassified subtype, with a median age of 45 years. The median histological tumor
diameter was 4.3 cm. TNBC were most often associated with a high grade, 49.2% grade III (53% for unclassified
subtype, 47.6% for basal-like). Vascular invasion was found in 26.6% of cases (22% for unclassified subtype and
28.3% for basal-like). For the lymph node involvement: 51% had positive lymph nodes, and 22.4% had distant
metastases. Neoadjuvant chemotherapy was administered to 18% patients with 26% of complete pathologic
response; therefore adjuvant chemotherapy was given to 82%. 98% received anthracycline based regimen and only
30% received taxanes.
The Kaplan-Meier curves based showed the lowest survival probability at 3-years (49% of OS, and 39% of DFS).
Conclusion: TNBC is associated with young age, high grade tumors, advanced stage at diagnosis, difference
chemo response compared to other subtypes, and shortest survival. Critical to optimal future management is
accurate identification of truly triple negative disease, and adequately powered prospective TNBC trials to establish
treatment efficacy and define predictive biomarkers.
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Breast cancer is a heterogeneous disease with different
morphologies, molecular profiles, clinical behavior and
response to therapy.
Triple-negative breast cancer (TNBC) is defined as a
group of breast carcinomas that are negative for expres-
sion of hormone receptors (ER, PR) and HER2, we can
distinguish between two groups: basal-like (ER-, PR-,
Her2-, cytokeratin (CK) 5/6+ and/or Her11+) and unclas-
sified subtype (ER-, PR-, Her2-, Her1- and CK5/6-). These
patients with triple-negative tumors have a relatively poor
outcome and cannot be treated with endocrine therapy or
therapies targeted to human epidermal growth factor
receptor type 2 (HER2), in contrast with hormonal recep-
tor positive and HER2+ breast cancers.
Given these characteristics, triple-negative breast
cancer is a challenge in today’s clinical practice.
The aim of this study is to determine the clinico-
pathological, histological, therapeutic and prognostic
features associated with this type of breast cancer.
It is critical to recognise that TNBC is a heterogeneous
disease, for which chemotherapy alone is inadequate for
the majority of patients. New treatment options are
urgently required.
Methods
This is a retrospective study of 366 female breast cancer
patients diagnosed between January 2007 and June 2010
at the Department of Pathology, Hassan II University
Hospital.
Epidemiological, clinical, histological, therapeutic and
evolutive data were analyzed.
The histological classification was based on the criteria
set by the World Health Organization. The histological
grade is based on the Scarff-Bloom-Richardson grading
system (SBR). It is based on a combined score for
nuclear grade, mitotic rate, and histologic grade or
architectural differentiation. Each characteristic is given
a score of 1 to 3, resulting in a total score ranging from
3t o9 .G r a d e1i n c l u d e st u m o r sw i t hc o m b i n e ds c o r e s
of 3, 4 or 5; grade 2 includes scores of 6 and 7; and
grade 3 includes tumors with the scores of 8 and 9.
Her2 immunohistochemical was carried out using the
HercepTest. Her2 score 2+ cases were analysed and
completed by FISH Method. They were performed using
the PathVysion HER2 DNA Probe (Abbott Vysis Inc.,
Downers Grove, IL) according to the manufacturer’s
protocol. The probe cocktail, including the LSI HER-2/
neu probe and the CEP17 probe. Fluorescence signals
were analyzed and digitalized using the CytoVision™
image analysis system (Applied Imaging International
Ltd., Newcastle-Upon-Tyne, UK). Between 60 and 100
nuclei were scored from each case. Signal ratios (HER2:
CEP17) of ≥ 2.2 were classified as amplified. In the
absence of positive FISH data, tumors scored 2+ by IHC
were considered negative for HER-2.
OS and DFS rates were estimated by Kaplan-Meier
analysis and a log-rank test to estimate the outcome. OS
was determined as the length of time from the date of
surgery until either the date of death (from any cause)
or the date of last follow-up. DFS was defined as the
length of time from the date of surgery to any relapse
or death.
Consent was obtained from the participants in this
research.
Ethical approval was not obtained in our research.
Results
A total of 64 patients with breast cancer, were identified
as having triple-negative breast cancer (17.5%), which
12.6% were basal-like (CK5/6 positive and or Her1 posi-
tives), 4.9% were unclassified subtype (CK5/6 and Her1
negatives), a median age and histological tumor dia-
meter were respectively 45 years and 4.3 cm (Table 1).
TNBC were most often associated with invasive ductal
carcinomas (78%), and a high grade, 49.2% grade III
(53% for unclassified subtype, 47.6% for basal-like),
47.5% grade II. However, 3.3% triple-negative breast
cancer were grade I (0% et 4.8% unclassified subtype
and basal-like respectively). A small percentage of can-
cer was diagnosed metaplasic carcinoma (9.4%) or
medullar carcinoma (6.3%).
Vascular invasion was found in 26.6% of cases (22%
for unclassified subtype and 28.3% for basal-like
subtype).
For the lymph node involvement: 51% had positive
lymph nodes, and 22.4% had distant metastases. For the
AJCC staging 17.2% were classified stage I, 20.7% stage
IIA, 13.8% stage IIB, 10.3% stage IIIA, 15.5% stage IIIB,
and 22.4% were metastatic.
For treatment modalities, 94% underwent surgery
(radical mastectomy in 40% of cases and 60% had con-
servative surgery). Neoadjuvant chemotherapy was
administered to 18% patients with 26% of complete
pathologic response; therefore adjuvant chemotherapy
was given to 82%. 98% received anthracycline based
regimen and only 30% received taxanes.
The Kaplan-Meier curves based showed the lowest
survival probability at 3-years (49% of OS, and 39% of
DFS) (Figure 1).
Discussion
A Pub Med search of the medical literature shows that
the first mention of “triple-negative” breast cancer was
in October 2005; since then, the term has appeared in
more than 600 publications [1]. This increase reflects
the growing recognition of the importance of TNBC by
oncologists, biologists, pathologists, and geneticists, as
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with breast cancer.
TNBC are defined as tumors that lack expression of
estrogen receptor (ER), progesterone receptor (PR), and
HER2.
Among the five intrinsic subgroups of breast cancer,
we identified basal like breast cancer by expression
genes profiling revealed by microarray test [2]. This
subgroup is characterized by an absence or low levels of
expression of ER, an absence of HER2, and expression
of genes usually found in basal or myoepithelial cells of
the normal breast (CK5/6+, Her1+) [2,3].
In this study, we have used the same definition of
TNBC.
TNBC generally occurs in younger women, less than
50 years, and is associated with a high risk of distant
recurrence and death, especially during the first 3-5
years of follow up [4,5]. Our series report the same
results, the TNBC group is associated with the high per-
centage of death (47%) and 64%of patients were aged
less than 50 years.
Some risk factors for developing basal-like breast can-
cers have been identified [6,7]. The association between
BRCA1 mutations and the development of TNBC is well
established [8]. A recent report suggests that BRCA1
mutations occur in close to 20% of sporadic TNBC and
are associated with improved prognosis [9]. It is
Figure 1 a Kaplan-Meier curve illustrating the disease-free
survival at 3 years of follow-up. b Kaplan-Meier curve illustrating
the overall survival at 3 years of follow-up.
Table 1 Description of the characteristics in the
population study
Characteristics %
Median age 45 years
Median histological tumor diameter 4.3 cm
Triple-negative breast cancer 17.5%
Basal-like 12.6%
Unclassified subtype 4.9%
Histological type
Invasive ductal carcinomas 78%
Metaplasic carcinoma 9.4%
Medullar carcinoma 6.3%
Other types 6.3%
Histological grade SBR
I 3.3%
II 47.5%
III 49.2%
Vascular invasion 26.6%
Positive lymph nodes 51%
Distant metastases 22.4%
AJCC staging
stage I 17.2%
stage IIA 20.7%
stage IIB 13.8%
stage IIIA 10.3%
stage IIIB 15.5%
metastatic 22.4%
Treatment modalities
Surgery 94%
Radical mastectomy 40%
Conservative surgery 60%
Chemotherapy
Neoadjuvant chemotherapy 18%
Adjuvant chemotherapy 82%.
Anthracycline based regimen 98%
Only taxanes 30%
Complete pathologic response 26%
Outcome
Overall survival at 3 years 49%
Disease-free survival at 3 years 39%
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more closely resemble claudin-low or basal-like TNBC.
Moreover, tumors arising in BRCA1 mutation carriers
illustrate sensitivity to poly-(ADP)-ribose polymerase
inhibitors, thus suggesting that mutated BRCA1 within
TNBC could be predictive of response to this novel
class of agents [10,11].
In the Carolina Breast Cancer Study, 20% of the
tumors were basal-like. In our series, 13% of the tumors
were basal-like. Our results demonstrated that the basal-
like subtype was most common among premenopausal
women (61%) compared with postmenopausal (39%)
similar to that reported by other series [12,13]. Interest-
ingly, a recent study of risk among different racial and
ethnic subtypes in the Women’s Health Initiative sug-
gested that among African American women, traditional
r i s kf a c t o r ss u c ha sm e n s t r u al and pregnancy history,
body mass index, and activity failed to explain differ-
ences in incidence from white women [14].
The grade III was the most common as in our series,
corresponding to 53% in unclassified subtype, 48% in
basal-like, 48% in Her2-overexpressing, 28% in luminal
B, 23% in luminal A (p = 0,005), which concord with
other studies such as Livasy et al. [15] who demon-
strated that the most consistent pathologic features for
basal-like subtype including high grade, high mitotic
count, geographic necrosis, pushing border, prominent
lymphocytic infiltrates, solid growth pattern, central
fibrotic/acellular area, and less association with ductal
carcinoma in situ.
Carey et al. [13] showed that a high mitotic index was
seen in 87% of basal-like subtype, 69% in the Her2-over-
expressing subtype, and only 31% and 32% in luminal A
and B subtypes, respectively. Secondly they showed a
marginally significant difference (p = 0.04) in the rate of
lymph node involvement, with the highest being among
Her2-overexpressing subtype (56%), followed by luminal
B (47%), basal-like (41%), and luminal A (34%). Our ser-
ies showed a non significant difference (p = 0,555)i n
the rate of the lymph node involvement, with the high-
est being among luminal B subtype (74%), followed by
Her2-overexperssing (66%), luminal A (63.5%), unclassi-
fied (61.5%), and basal-like (55%).
The basal-like and Her2-overexpressing subtypes have
the shortest survival, luminal A has the longest survival,
and luminal B has an intermediated prognosis [16].
These results are similar to our series. The Kaplan-
Meier curves based on the subclasses from Figure 1
showed a highly significant difference in OS at 3-years
between the subtypes (Figure 1a, Log-Rank test: p =
0,042), with the triple negative subtype associated with
the lowest survival probability (52%), but the luminal A
was associated with the best survival probability (88%)
compared to those in the other subtypes (77% for lumi-
nal B, 75% for Her2-overexpressing). These subtypes
also differed significantly in 3-years DFS (Figure 1b,
Log-Rank test: p = 0.002): luminal A (59%), luminal B
(41%), Her2-overexpressing (38%) and triple negative
(39%). Breast cancer patients with TNBC tumors had a
poorer prognosis in terms of DFS and OS than those
with luminal A tumors in the present study as pre-
v i o u s l yi n d i c a t e di nt h er e p o r tb yt h em o s ts t u d i e s .
Although some reports suggest that they respond to
chemotherapy better than other types of breast cancer,
prognosis remains poor.
This is due to poor disease-free intervals in the adju-
vant and neoadjuvant setting, shortened progression-free
survival associated to a more aggressive clinical course
in the metastatic setting, and the lack of targeted
therapy.
TNBC have a good initial response to chemotherapy,
particularly anthracycline and taxanebased therapy.
Although these tumors are initially sensitive to standard
neoadjuvant chemotherapy, they continue to exhibit a
short disease-free survival [17].
Rouzier et al. [18] evaluated complete pathologic
response with standardized neoadjuvant therapy among
82 patients, and found that the complete pathologic
response rates were 45% for basal-like and Her2-overex-
pressing subtypes and only 6% for luminal subtypes
Goldstein et al. [19] also demonstrated that there is
differential chemoresponse in different subtypes, with
basal-like and Her2-overexpressing subtype being more
sensitive, luminal A being more resistant, and luminal B
being intermediate.
Carey et al. showed that basal-like and Her2-overex-
pressing subtypes are more sensitive to anthracycline-
based neoadjuvant chemotherapy compared with lumi-
nal breast cancer [20].
Recently published neoadjuvant studies have clarified
the fact that patients who have a good pathologic out-
come from surgery also have a good clinical response.
However, within the group of patients who have residual
disease after completing neoadjuvant chemotherapy, a
poorer prognosis is seen in the triple-negative subgroup
[20].
But in our series, after neoadjuvant chemotherapy
based on anthracyclines and taxanes, complete patholo-
gic response was estimated as 62% in luminal A, 26% in
triple negative breast cancer, and 12% in Her2-overex-
pressing subtype. The few percentage of complete
pathologic response in Her2-overexpressing was
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hospital during the study period.
Currently, a major challenge is to identify target mole-
cules for basal-like subtype. Some of the possible mole-
cular targets for basal tumors that have been proposed
include EGFR and vascular endothelial growth factor
[21]. The c-kit, overexpressed in up to 31% of basal-like
subtype, seems not to be a suitable target at present,
because it lacks the activated mutation in breast cancer
that conveys sensitivity to imatinib [22].
The lack of therapeutic effect of imatinib was shown
in a phase II study of unselected patients with meta-
static breast cancers [23]. To complicate the matter
even further, a recent report has suggested, that the
same chemotherapeutic agents may have different
mechanisms of action indifferent subtypes of breast can-
cers [24].
X-linked inhibitor of apoptosis protein (XIAP) is a
viable novel biomarker and prognostic factor for inva-
sive ductal breast cancer with triple-negative phenotype.
The expression of XIAP is significantly correlated with a
more aggressive tumor phenotype and decreased OS
and DFS [25].
Conclusion
Triple-negative breast cancer is associated with young
age, high grade tumors, advanced stage at diagnosis, dif-
ference chemo response compared to other subtypes,
and shortest survival.
Critical to optimal future management are accurate
identification of truly triple negative disease and ade-
quately powered prospective TNBC trials to establish
treatment efficacy and define predictive biomarkers.
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